VBL Presents Human Proof-of-Concept Data That Show the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Multiple ...
September 11 2020 - 8:00AM
VBL Therapeutics (Nasdaq: VBLT), today presents for the first time
new data demonstrating ex-vivo activity of its proprietary
investigational anti-MOSPD2 mAbs in patients with
relapsing-remitting and progressive multiple sclerosis (MS). VBL's
study is being presented at the MS Virtual 2020, the virtual 8th
Joint ACTRIMS-ECTRIMS Meeting.
Data show that VBL's anti-MOSPD2 mAbs significantly inhibited
migration of monocytes isolated from all MS patients included in
the study (n=33) by up to 97%, regardless of disease severity,
gender or active treatment. Notably, the activity was seen not only
in the monocytes from relapsing-remitting, but also those from
primary progressive and secondary progressive patients with high
Expanded Disability Status Scale (EDSS) scores of 5.5-6.5.
“We believe our antibodies open up a completely novel mechanism
for potential treatment of MS, through blocking the accumulation of
monocytes/macrophages in the central nervous system,” said Itzhak
Mendel, Ph.D., Immunology Director of VBL Therapeutics. “This
mechanism is differentiated from the existing available treatments,
which mostly target T and B cells and therefore, it is not
surprising that our antibodies showed activity on top of any
patient active therapy. Backed up by strong preclinical results,
these first patient-driven proof-of-concept data reinforce the
therapeutic potential of our MOSPD2 program.”
VBL is currently advancing lead anti-MOSPD2 candidate VB-601
through IND-enabling studies, aiming to start a first-in-human
study in 2H 2021.
For a link to VBL's presentation at the MS Virtual 2020
conference, see: LINK
About VBL's VB-600 PlatformVBL is conducting
two parallel drug development programs that are exploring the
potential of MOSPD2 (motile sperm domain-containing protein 2), a
protein that VBL has identified as a key regulator of cell
motility, as a therapeutic target for inflammatory diseases and
cancer. Our VB-600 platform comprises classical anti-MOSPD2
monoclonal antibodies for inflammatory indications, as well as
bi-specific antibody candidates for oncology.
About VBLVascular Biogenics Ltd., operating
as VBL Therapeutics, is a clinical stage biopharmaceutical
company focused on the discovery, development and commercialization
of first-in-class treatments for areas of unmet need in cancer and
immune/inflammatory indications. VBL has developed three platform
technologies: a gene-therapy based technology for targeting newly
formed blood vessels with focus on cancer, an antibody-based
technology targeting MOSPD2 for anti-inflammatory and
immuno-oncology applications, and the Lecinoxoids, a family of
small-molecules for immune-related indications. VBL’s lead oncology
product candidate, ofranergene obadenovec (VB-111), is a
first-in-class, targeted anti-cancer gene-therapy agent that is
being developed to treat a wide range of solid tumors. It is
conveniently administered as an IV infusion once every 6-8 weeks.
It has been observed to be well-tolerated in >300 cancer
patients and demonstrated activity signals in a VBL-sponsored “all
comers” Phase 1 trial as well as in three VBL-sponsored
tumor-specific Phase 2 studies. Ofranergene obadenovec is currently
being studied in a VBL-sponsored Phase 3 potential registration
trial for platinum-resistant ovarian cancer.
Forward Looking Statements This press release
contains forward-looking statements. All statements other than
statements of historical fact are forward-looking statements, which
are often indicated by terms such as “anticipate,” “believe,”
“could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,”
“may,” “plan,” “potential,” “predict,” “project,” “should,” “will,”
“would” and similar expressions. These forward-looking statements
may include, but are not limited to, statements regarding our
programs, including MOSPD2, including their clinical development,
therapeutic potential and clinical results. These forward-looking
statements are not promises or guarantees and involve substantial
risks and uncertainties. Among the factors that could cause actual
results to differ materially from those described or projected
herein include uncertainties associated generally with research and
development, clinical trials and related regulatory reviews and
approvals, the risk that historical clinical trial results may not
be predictive of future trial results, the impact of the COVID-19
pandemic on our business, operations, clinical trials, supply
chain, strategy, goals and anticipated timelines and clinical
results, that our financial resources do not last for as long as
anticipated, and that we may not realize the expected benefits of
our intellectual property protection. A further list and
description of these risks, uncertainties and other risks can be
found in our regulatory filings with the U.S. Securities and
Exchange Commission, including in our annual report on Form 20-F
for the year ended December 31, 2019, and subsequent filings
with the SEC. Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. VBL
Therapeutics undertakes no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise.
INVESTOR CONTACT:Michael RiceLifeSci Advisors,
LLC(646) 597-6979
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2023 to Apr 2024